Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)

被引：1
|
作者：
Sajeev, G. [1 ]
Evans, R. [2 ]
Hawkins, N. [2 ,3 ]
Mahajan, A. [4 ]
Scott, D. [2 ]
Nam, J. [5 ]
Sutherland, S. [5 ]
Kokaliaris, C. [5 ,6 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Visible Analyt, Oxford, England
[3] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
[4] Bridge Med Consulting Ltd, London, England
[5] F Hoffmann La Roche Ltd, Global Access, Basel, Switzerland
[6] Roche Prod Ltd, Welwyn Garden City, Herts, England
来源：
NEUROMUSCULAR DISORDERS | 2023年 / 33卷
关键词：
D O I：
10.1016/j.nmd.2023.07.385
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P08
引用
收藏
页码：S164 / S164
页数：1
相关论文
共 50 条
  • [1] Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy
    Kokaliaris, Christos
    Evans, Rachel
    Hawkins, Neil
    Mahajan, Anadi
    Scott, David Alexander
    Sutherland, C. Simone
    Nam, Julian
    Sajeev, Gautam
    ADVANCES IN THERAPY, 2024, 41 (06) : 2414 - 2434
  • [2] Children with spinal muscular atrophy treated with nusinersen/risdiplam
    Chacko, A.
    Sly, P.
    Deegan, S.
    Young, E.
    Gauld, L.
    RESPIROLOGY, 2023, 28 : 204 - 205
  • [3] Children With Spinal Muscular Atrophy Treated With Nusinersen/Risdiplam
    Chacko, A.
    Sly, P. D.
    Deegan, S.
    Young, E.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [4] Switching from Nusinersen to Risdiplam in Spinal Muscular Atrophy: A Comparative Analysis of Safety, Efficacy, and Economic Impact
    Castellana, Eleonora
    HOSPITAL PHARMACY, 2025, 60 (02) : 103 - 104
  • [5] Language development in spinal muscular atrophy (SMA) type 1 children treated with nusinersen
    Brusa, C.
    Scoto, M.
    Manzur, A.
    Main, M.
    Muntoni, F.
    Vargha-Khadem, F.
    Baranello, G.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S187 - S187
  • [6] Evaluating the respiratory health of children with spinal muscular atrophy (SMA) type 1 on Nusinersen
    Grime, Chris
    Edel, Lisa
    Robinson, Victoria
    Rendel, Gareth
    Abel, Francois
    Chan, Elaine
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [7] Safety of risdiplam in spinal muscular atrophy patients after short-term treatment with nusinersen
    Yan, Yue
    Feng, Yijie
    Jiang, Liya
    Jin, Jianing
    Mao, Shanshan
    MUSCLE & NERVE, 2024, 70 (05) : 1095 - 1098
  • [8] FIREFISH Parts 1 and 2: 4-year efficacy and safety of risdiplam in Type 1 spinal muscular atrophy (SMA)
    Mazurkiewicz-Beldzinska, M.
    Baranello, G.
    Boespflug-Tanguy, O.
    Day, J.
    Deconinck, N.
    Klein, A.
    Masson, R.
    Mercuri, E.
    Rose, K.
    Servais, L.
    Vlodavets, D.
    Xiong, H.
    Zanoteli, E.
    El-Khairi, M.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Palfreeman, L.
    Dodman, A.
    Darras, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 196 - 196
  • [9] IREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in type 1 spinal muscular atrophy (SMA)
    Masson, R.
    Boespflug-Tanguy, O.
    Darras, B.
    Day, J.
    Deconinck, N.
    Klein, A.
    Mazurkiewicz-Beldzinska, M.
    Mercuri, E.
    Rose, K.
    Servais, L.
    Vlodavets, D.
    Xiong, H.
    Zanoteli, E.
    Dodman, A.
    El-Khairi, M.
    Gaki, E.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Baranello, G.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S134 - S134
  • [10] FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA)
    Darras, Basil
    Baranello, Giovanni
    Boespflug-Tanguy, Odile
    Day, John
    Deconinck, Nicholas
    Klein, Andrea
    Masson, Ricardo
    Mazurkiewicz-Beldzinska, Maria
    Mercuri, Eugenio
    Rose, Kristy
    Vlodavets, Dmitry
    Xiong, Hui
    Zanoteli, Edmar
    El-Khairi, Muna
    Gerber, Marianne
    Gorni, Ksenija
    Kletzl, Heidemarie
    Palfreeman, Laura
    Dodman, Angela
    Servais, Laurent
    NEUROLOGY, 2023, 100 (17)
12345